DE69221069D1 - Hemmung von metastasen bei krebspatienten mit pyridyloxazol-2-onen - Google Patents

Hemmung von metastasen bei krebspatienten mit pyridyloxazol-2-onen

Info

Publication number
DE69221069D1
DE69221069D1 DE69221069T DE69221069T DE69221069D1 DE 69221069 D1 DE69221069 D1 DE 69221069D1 DE 69221069 T DE69221069 T DE 69221069T DE 69221069 T DE69221069 T DE 69221069T DE 69221069 D1 DE69221069 D1 DE 69221069D1
Authority
DE
Germany
Prior art keywords
pyridyloxazole
metastases
inhibition
cancer patients
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69221069T
Other languages
English (en)
Other versions
DE69221069T2 (de
Inventor
Alan Bitonti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69221069D1 publication Critical patent/DE69221069D1/de
Publication of DE69221069T2 publication Critical patent/DE69221069T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69221069T 1991-05-14 1992-04-14 Hemmung von metastasen bei krebspatienten mit pyridyloxazol-2-onen Expired - Fee Related DE69221069T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69982191A 1991-05-14 1991-05-14
PCT/US1992/003062 WO1992020337A2 (en) 1991-05-14 1992-04-14 Inhibition of metastasis in patients having cancer with pyridyloxazole-2-ones

Publications (2)

Publication Number Publication Date
DE69221069D1 true DE69221069D1 (de) 1997-08-28
DE69221069T2 DE69221069T2 (de) 1997-11-13

Family

ID=24811050

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69221069T Expired - Fee Related DE69221069T2 (de) 1991-05-14 1992-04-14 Hemmung von metastasen bei krebspatienten mit pyridyloxazol-2-onen

Country Status (12)

Country Link
US (1) US5610171A (de)
EP (1) EP0539575B1 (de)
AT (1) ATE155686T1 (de)
AU (1) AU645217B2 (de)
CA (1) CA2087334A1 (de)
DE (1) DE69221069T2 (de)
DK (1) DK0539575T3 (de)
ES (1) ES2106874T3 (de)
GR (1) GR3024832T3 (de)
IE (1) IE921524A1 (de)
NZ (1) NZ242677A (de)
WO (1) WO1992020337A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009529A1 (en) * 2002-03-26 2007-01-11 New York University Agents that dissolve arterial thrombi
US8753631B2 (en) * 2009-05-01 2014-06-17 New York University Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2935902A1 (de) * 1979-09-05 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln Oxazolinalkansaeuren, deren salze und ester, verfahren zu deren herstellung und diese enthaltende arzneimittel
US4728661A (en) * 1985-11-13 1988-03-01 Merrell Dow Pharmaceuticals Inc. Cardiotonic phenyl oxazolones
US4698353A (en) * 1985-11-13 1987-10-06 Merrell Dow Pharmaceuticals Inc. Cardiotonic heterocyclic oxazolones
US4670450A (en) * 1985-11-13 1987-06-02 Merrell Dow Pharmaceuticals Inc. Cardiotonic thiazolones
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5182293A (en) * 1989-11-13 1993-01-26 Merrell Dow Pharmaceuticals Inc. Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
ZA908852B (en) * 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones

Also Published As

Publication number Publication date
IE921524A1 (en) 1992-11-18
ES2106874T3 (es) 1997-11-16
EP0539575B1 (de) 1997-07-23
US5610171A (en) 1997-03-11
WO1992020337A2 (en) 1992-11-26
AU2167692A (en) 1992-12-30
DK0539575T3 (da) 1997-10-27
AU645217B2 (en) 1994-01-06
DE69221069T2 (de) 1997-11-13
NZ242677A (en) 1997-06-24
GR3024832T3 (en) 1998-01-30
EP0539575A1 (de) 1993-05-05
WO1992020337A3 (en) 1993-01-21
CA2087334A1 (en) 1992-11-15
ATE155686T1 (de) 1997-08-15

Similar Documents

Publication Publication Date Title
DE706657T1 (de) Wechselwirkungen von inhibierungsproteinen
DK0981607T3 (da) Modificeret arginin-deiminase
LU88359I2 (fr) Claritine
DE60035204D1 (de) Tyrosinderivate
ATE164593T1 (de) Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
DE69131458T2 (de) Hardware-Anordnung zur Addition und Subtraktion von Gleitkommazahlen
FI941580A0 (fi) Bisyklisiä ansamysiinejä
DE69431458T2 (de) Echtheitsüberprüfung von Gegenständen
DE69212777D1 (de) Verhinderung von Korrosion und Ablagerungen
NO892866D0 (no) Inhibering av korrosjon i oljefelter.
DE69220382D1 (de) Verwendung von Peptidderivaten
DK0827537T3 (da) Chromatin-regulator-gener
DE69226763T2 (de) Härten von fluoroelastomeren
DE69104947D1 (de) Verhütung von Kesselstein.
FR2686425B1 (fr) Source sismique de puits.
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
DE69232265T2 (de) Induktion von cytolytischen t-lymphocyten mit polypeptiden des cytomegalievirus
DK162190D0 (da) Revers-transcriptase-inhibitorer til behandling af adenocarcinomaer
DE69231390D1 (de) Anisotropische Ablagerung von Dielektrika
NO940771L (no) Kollagenfremkalt blodplateaggregeringsinhibitor
DE69221069D1 (de) Hemmung von metastasen bei krebspatienten mit pyridyloxazol-2-onen
DE69218364D1 (de) Verwendung von 17B-N-Mono-substituierten Carbamoyl-4-aza-5a-androst-1-en-3-onen zur Herstellung von Arzneimitteln zur Verhütung von Prostata Karzinomen
DE69208681D1 (de) Verwendungen von 1,1,1,3,3,3-hexafluoropropan
ATE79255T1 (de) Wirkstoffe zur verhuetung von tumormetastasen.
DE69311284D1 (de) Verwendung von Bohrflüssigkeiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee